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Summary 
Induced pluripotent stem cells (iPSC) are generated from mouse and human fibroblasts 
by the introduction of three transcription factors, namely Oct3/4, Sox2, and Klf4. The 
protooncogene product c-Myc markedly promotes iPSC generation, but it also increases 
tumor formation in iPSC-derived chimera mice. We herein show that the promotion of 
iPSC generation by Myc is independent of its transformation property. We found that 
another Myc family member called L-Myc, as well as c-Myc mutants (W136E and dN2), 
which all possesses little transformation activity, promoted human iPSC generation 
more efficiently and specifically than did the wildtype c-Myc. In mice, L-Myc promoted 
germline transmission, but not tumor formation, in the iPSC-derived chimera mice. 
These data demonstrated that different functional moieties of the Myc protooncogene 





Induced pluripotent stem cells (iPSC) were first generated from mouse fibroblasts by 
the retroviral introduction of four transcription factors, Oct3/4, Sox2, Klf4, and c-Myc 
(1). Mouse iPSC are indistinguishable from embryonic stem cells (ESC) in morphology, 
proliferation and gene expression. Furthermore, mouse iPSC give rise to chimeric mice 
which are competent for germline transmission (2-4). However, we found that both the 
chimeras and progenies derived from mouse iPSC showed an increased incidence of 
tumor formations, primarily due to the reactivation of the c-Myc retrovirus (3). 
Subsequently, we and others succeeded in making mouse iPSC without the c-Myc 
retrovirus by modifying the induction protocol (5, 6). Chimeric mice derived from these 
c-Myc-minus iPSC did not show any increased incidence of tumor formation (6). 
However, the efficiency of iPSC generation is significantly lower without the c-Myc 
retrovirus. Indeed, c-Myc is utilized in most of the reported methods to generate iPSC 
without viral integrations (7-15). Therefore, c-Myc functions as a double-edged sword in 
that it promotes both iPSC generation and tumorigenicity.  
In addition to the overexpression of c-Myc, we and others have shown the suppression of 
the tumor suppressor gene p53 to also significantly enhance iPSC generation (16-19). 
The downstream targets of p53, including p21 and Arf/Ink4, are also involved in the 
suppression of iPSC generation. The fact that the two most common pathways 
associated with human cancers, namely the activation of c-Myc and the suppression of 
p53, both substantially enhance iPS generation raise the possibility that the molecular 
mechanisms underlying iPSC generation and tumorigenicity thus largely overlap. 
The Myc protooncogene family consists of three members; c-Myc, N-Myc, and L-Myc 
(20-23). All three members dimerize with Max and binding to DNA (24). N-Myc is 
similar to c-Myc regarding its length, domain structures, and frequent association with 
human cancers (25). In contrast, the L-Myc protein demonstrates shorter amino acid 
sequences than the other two members in the N-terminal region, while also possessing a 
significantly lower transformation activity in cultured cells (21, 26-29). Consistent with 
this property, only a small number of human cancers have been associated with the 
aberrant expression of L-Myc. In this study, we analyzed the effect of L-Myc in the 
promotion of iPSC generation. Despite its weak transformation activity, we found L-Myc 
to have a stronger and more specific activity in promoting iPSC generation. We also 
found that the mutations which significantly deteriorate the transformation activity of 
c-Myc more effectively and specifically promoted human iPSC generation. These results 
demonstrated that the promotion of nuclear-reprogramming and transformation 
activity are independent properties of the Myc family proteins. 
Results 
In order to compare the effects of L-Myc, N-Myc, and c-Myc on human iPSC 
generation, we retrovirally transduced human adult dermal fibroblasts with Oct3/4, 
Sox2, and Klf4, with or without the Myc family members. Three weeks thereafter, we 
counted the numbers of both iPSC colonies, which showed an ES cell-like morphology 
with a flat and round shape and characterized by a distinct edge, as well as non-iPSC 
colonies which were granules and demonstrated an irregular edge. We thus found 
L-Myc to have a significantly more potent ability to increase the number of iPSC 
colonies than c-Myc (Figure 1A). N-Myc also tended to increase the iPSC colonies more 
effectively than did c-Myc, albeit the difference was not statistically significant. We also 
found that c-Myc and N-Myc markedly increased the formation of non-iPSC colonies, 
whereas L-Myc did not show any such effect. As a result, the proportion of iPSC colonies 
to total colonies is significantly higher with L-Myc than with c-Myc or N-Myc (Figure 
1B). 
Human iPSC generated with L-Myc showed a morphology similar to that of 
hESC (Figure 1C). They are positive for various pluripotent markers, such as Tra-1-60, 
Tra-1-81, SSEA-3, and Oct3/4 (Figure S1A). They differentiated into various tissues of 
three germ layers, including neural tissues, gut-like epithelial cells, cartilage, and 
adipose tissue, in teratomas (Figure S1B) and in embryoid bodies (Figure S1C). They 
have normal karyotypes (Figure S1D). These results demonstrated that L-Myc more 
specifically and effectively promotes human iPSC generation than does c-Myc.  
 We next compared the three Myc members in mouse iPSC generation. Mouse 
embryonic fibroblasts (MEF), which have a GFP-reporter driven by the regulatory 
regions of the mouse Nanog gene, were retrovirally transduced with Oct3/4, Sox2, and 
Klf4, with or without each of the Myc family members. Three weeks thereafter, we 
counted the numbers of GFP-positive and GFP-negative colonies. GFP-positive colonies 
represent fully reprogrammed iPSC, whereas GFP-negative colonies represent partially 
reprogrammed cells or transformed cells. As has been reported previously (6), all the 
three Myc proteins enhanced generation of GFP-positive colonies (Figure 2A). The effect 
of c-Myc is stronger than the other two members, but it increased the number of 
GFP-negative colonies more profoundly than the GFP-positive ones, thus resulting in a 
significant decrease in the proportion of GFP-positive colonies to total colonies (Figure 
2B). In contrast, L-Myc preferentially increased GFP-positive colonies, while the 
proportion of GFP-positive colonies to the total colonies remained high. These results 
demonstrated that L-Myc specifically enhances the generation of fully reprogrammed 
mouse iPSC. 
 Mouse iPS cells generated with L-Myc showed an ES-like morphology (Figure 
S2A) and express pluripotent-associated genes, such as Nanog, Rex1, ECAT1, and ESG1 
(Figure S2B). The expression of retroviral transgenes was effectively silenced. When 
transplanted subcutaneously into nude nice, they formed teratomas containing various 
tissues, such as neural tissues, gut-like epithelial tissues and striated muscles (Figure 
S2C). Furthermore, when injected into blastocysts, L-Myc iPS cells were capable of 
producing high percentage chimeras, which were competent for germline transmission. 
Of note, we found that both c-Myc and L-Myc promoted germline transmission from 
chimeras in comparison to iPS cells generated without the Myc transgenes (Figure 3A). 
Therefore, iPSC generated with L-Myc are of a comparable quality to ES cells.  
 We have previously shown that iPSC generated with the c-Myc retrovirus 
resulted in a markedly increased tumor formation and mortality in chimeras and 
progeny mice (3, 30). In contrast, iPSC generated without the c-Myc transgene did not 
show any such adverse effects in mice (6). In this study, we observed chimeras derived 
from L-Myc iPSC clones up to two years. In great contrast to c-Myc, the L-Myc 
retrovirus did not result in any marked increase in either tumorigenicity or mortality 
(Figure 3B). When compared to chimeric mice derived from Myc-minus iPS cells, L-Myc 
iPS cells did show a slightly higher mortality, but not tumorigenicity, in mice after one 
year from birth. Causes of death in these mice are yet to be determined. This result is 
consistent with the weak transformation activity of L-Myc.  
 We also examined whether L-Myc was capable of decreasing the number of 
factors required for iPSC generation. We found that with the addition of L-Myc, iPSC 
can be generated without Sox2. When 1 x 105 Nanog-GFP reporter MEFs were infected 
with Oct3/4, Klf4, and L-Myc, we obtained 16 GFP-positive colonies. In contrast, we did 
not obtain any GFP-positive colonies without the L-Myc transgene. We picked up all of 
these colonies and were able to establish iPSC lines from 15 clones. These Sox2-minus 
iPSC showed an ES-like morphology (Figure S3A) and express ES cell markers such as 
Nanog, Rex1, and ECAT1 (Figure S3B).  We confirmed the absence of the Sox2 
transgene by genomic PCR (Figure S3C). These cells can differentiate into cells of three 
germ layers in teratomas (Figure S3D) and in embryoid bodies (Figure S3E).  
Sox2-minus L-Myc iPS cells were capable of producing chimeras, which were competent 
for germline transmission (Figure S3F). 
We next examined the correlation between the ability to promote iPSC 
generation and the transformation activity of the Myc proteins. We constructed the 
W136E c-Myc mutant which has been reported to lack transformation activity, but it 
still binds to Max and DNA (26, 31). We also generated a mutant of c-Myc that does not 
bind to Miz-1 (V394D) (32) and other mutants of c-Myc and L-Myc that do not bind to 
Max (c-Myc L420P and L-Myc L351P) (33). We confirmed that the wildtype L-Myc, the 
W136E c-Myc mutant, the L420P c-Myc mutant, and the L351P L-Myc mutant showed 
little transformation activity in NIH3T3 cells (Figure 4A). In contrast, the wildtype 
c-Myc and the V394D c-Myc mutant induced transformation is characterized by a high 
refractivity and a spindle-like shape. We then introduced either the wildtype or the 
mutant c-Myc into adult human dermal fibroblasts together with Oct3/4, Sox2, and Klf4 
to generate iPSC colonies. We found the W136E c-Myc mutant to function in a similar 
manner to that of L-Myc; it increases the number of iPSC colonies more effectively than 
the wildtype c-Myc (Figure 4B). The proportion of iPSC colonies to total colonies was 
also higher with the W136E mutant that with the wildtype c-Myc (Figure S4A). The 
V394D c-Myc mutant was comparable to the wildtype c-Myc, thus indicating that the 
binding to Miz-1 does not play positive nor negative roles in the promotion of iPSC 
generation. The L420P c-Myc or L351P L-Myc mutant did not promote iPSC generation, 
thereby demonstrating the essential role of Max binding. Similar results were obtained 
in mice (Figure S4C and D); the W136E c-Myc mutant, like L-Myc, specifically promoted 
mouse iPSC generation, whereas the V394D c-Myc mutant, like the wildtype c-Myc, 
promoted both iPSC and non-iPSC generation.  
We also constructed c-Myc mutants that have a shorter N-terminus; dN1 and 
dN2. The c-Myc protein is ~22 amino acids longer than L-Myc in the N-terminus. These 
extra amino acids were deleted in the dN2 mutant, whereas only 14 amino acids were 
deleted in the dN1 mutant. We found that the dN2 mutant showed little transformation 
activity in NIH3T3 cells, whereas the dN1 mutant was comparable to the wildtype 
c-Myc (Figure 4C). The dN2 mutant showed a similar property with the wildtype L-Myc 
and the W136E c-Myc mutant during iPSC generation in both human (Figure 4D and 
S4B) and mouse (Figure S4E and F). In contrast, the dN1 mutant was comparable to 
the wildtype c-Myc. These data, taken together, showed that the promotion of iPSC 
generation by Myc therefore is not parallel to its transformation activity. 
To elucidate the molecular mechanisms underlying the different effects of 
c-Myc and L-Myc during iPSC generation, we performed DNA microarray analyses. We 
expressed either c-Myc (wildtype, W136E, V394D, or L420P) or L-Myc (wildtype or 
L351P) in human adult dermal fibroblasts by retroviruses. Two days after transduction, 
we isolated total RNA for microarray analyses. We categorized genes that either 
increased or decreased more than two-fold by Myc into four groups as follows: group A, 
increased > 2-fold by wildtype c-Myc and the V394D c-Myc mutant compared to 
mock-transduced control (Mock) and the L420P c-Myc mutant; group B, decreased > 
2-fold by wildtype c-Myc and the V394D c-Myc mutant compared to Mock and the 
L420P c-Myc mutant; group C, increased > 2-fold by wildtype L-Myc and the W136E 
c-Myc mutant compared to Mock and the corresponding Max-biding deficient mutant; 
and group D, decreased > 2-fold by wildtype L-Myc and the W136E c-Myc mutant 
compared to Mock and the Max-biding deficient mutant. Groups A and B represent the 
genes regulated by Myc proteins which promote both iPSC generation and 
transformation. Groups C and D represent genes regulated by Myc proteins which 
specifically promote iPSC generation, but not transformation. 
We found that c-Myc and L-Myc regulate both common (subgroups AC and BD 
in Figure 5A) and unique target genes (subgroups A, C, B, and D in Figure 5A) Genes in 
each subgroup are shown in Supplementary Table 1. Subgroups A and AC are 
enriched with genes that are highly expressed in human ES cells as well as cancer cells, 
such as bladder tumors and nasopharyngeal carcinoma (NPC) (Figure 5B and C). The 
increased expression of these genes may be associated with the transformation activity 
of Myc. In contrast, subgroups BD and D are enriched with genes which are highly 
expressed in fibroblasts, but not in ESC or iPSC. This result suggests that the 
promotion of iPSC generation by Myc might be associated with the suppression of 
fibroblast-specific genes and that L-Myc is more potent than c-Myc in this specific gene 
regulation. 
Discussion 
In the current study, we found that L-Myc shows the strongest and the most 
specific activity in promoting human iPSC generation among the three Myc family 
proteins, c-Myc, N-Myc, and L-Myc. This was surprising since L-Myc has been shown to 
have the weakest transformation activity among the three proteins (21, 25, 26, 28). We 
also found that the mutations which deteriorate the transformation activity of c-Myc 
specifically promote iPSC generation. Our findings demonstrated that iPSC generation 
and transformation utilize different functional moieties of the Myc protooncogene 
products. 
DNA microarray analyses suggested that L-Myc and the 
transformation-deficient W136E c-Myc mutant have the different target genes from the 
wildtype c-Myc. When overexpressed in human dermal fibroblasts, L-Myc and the 
W136E c-Myc mutant suppressed many genes that were highly expressed in fibroblasts 
in comparison to iPSC or ESC. In contrast, only a small number of genes were 
selectively activated by L-Myc and the W136E c-Myc. We therefore postulate that the 
primary role of these Myc proteins in promoting iPSC generation might be to suppress 
differentiation-associated genes. This finding is consistent with a previous report about 
c-Myc (34) and we also found both L-Myc and the W136E c-Myc mutant to be more 
potent than the wildtype c-Myc . 
DNA microarray analyses also found that the wildtype c-Myc protein activates 
many genes that are enriched not only in ESC and iPSC, but also in cancer cells. These 
gene products might be associated with cell proliferation, immortality and cell 
metabolisms. Approximately a half of these are specifically activated by the wildtype 
c-Myc, but not by L-Myc or the W136E c-Myc mutant. These genes are might be 
responsible, at least in part, for the transformation activity of c-Myc. 
We found that the effects of L-Myc and the transformation-deficient mutants of 
c-Myc in enhancing iPSC generation were more potent in human than in mouse. 
Reasons for this discrepancy are yet to be determined. It may suggest that molecular 
mechanisms underlying iPSC generation might be similar, but not identical, between 
human and mouse. 
Since its first demonstration in 2006, iPSC generation has been associated with 
transformation and tumorigenicity (1). First of all, all the four factors required for iPSC 
generation have been associated in human cancers. The most obvious example is c-Myc, 
one of the first protooncogene identified in human cancers (35). The aberrant expression 
of c-Myc is found in more than fifty percent of human cancers. Klf4 plays a unique role 
in cancers in that it functions as both a protooncogene and a tumor suppressor gene (36). 
Klf4 promotes cellular transformation by suppressing p53, but it also enhances the 
activity of p21, and therefore it may function as a tumor suppressor depending on the 
cellular context (37). The aberrant expression of Oct3/4 and Sox2 has also been found in 
some germ cell tumors and other tumors (38-42). 
The association of iPSC generation and transformation has also become 
evident by the increased incidence of tumor formation observed in chimeric mice 
derived from iPSC (3, 30). More than fifty percent of chimeras derived from 
MEF-derived four factors-induced iPSC developed tumors within one year after birth. 
In these tumors, a reactivation of the c-Myc retrovirus was detected. In contrast, 
chimeras derived from iPSC generated without the c-Myc retrovirus did not show any 
such increased incidence of tumorigenicity (6). Therefore, c-Myc seems to play a major 
role in the observed tumorigenicity in iPSC-derived mice. 
More recently, multiple groups have independently shown the suppression of 
the tumor-suppressor gene p53 to markedly enhance iPSC generation (16-19). The loss 
of the p53 functions, like the aberrant expression of c-Myc, has been associated with 
many human tumors (43-47). All of these findings, taken together, indicate that iPSC 
generation and cellular transformation have many molecular mechanisms and 
pathways in common, and therefore increasing the efficacy of iPSC generation can be 
achieved at the expense of increased tumor formation. 
In contrast to these predictions, our data showed that iPSC generation and 
transformation by Myc are largely independent. The former was mainly attributable to 
the suppression of genes that are highly expressed in fibroblasts, but not in iPSC or 
ESC. In contrast, transformation is attributable to the activation of genes that are 
enriched in highly proliferative cells, including cancer cells, iPSC and ESC. Although 
methods of iPSC generation which do not result in permanent integration of transgenes 
have been reported (7-15), even the transient expression of the c-Myc transgene may 
cause detrimental effects on the resulting iPSC. Therefore, the usage of L-Myc or 
transformation-deficient mutants of c-Myc should be beneficial for the future clinical 
applications of iPSC technologies. 
Materials and Methods 
Plasmid constructions 
pMXs-based retroviral vectors for the mouse Myc family genes have been described 
previously (6). The coding regions of human L-Myc and N-Myc were amplified by 
RT-PCR with primers listed in Supplementary Table 2. N-terminus deleted c-Myc 
mutants (cdN1; 14-439 aa, cdN2; 42-439 aa) were amplified by the PCR primers listed 
in Supplementary Table 3. These PCR products were subcloned into 
pENTR-D-TOPO (Invitrogen), and recombined with pMXs-gw by the LR reaction 
(Invitrogen). For the construction of Myc point mutants, site-directed mutagenesis was 
performed using PrimeSTAR HS DNA Polymerase (Takara, Japan) with primers listed 
in Supplementary Table 4, according to the manufacturer’s instructions. 
 
Generation of iPSC 
The induction of mouse iPSC was performed as previously described (1, 3, 6) with some 
modifications. Briefly, mouse embryonic fibroblasts (MEF) which contained the 
Nanog-GFP-IRES-Puror reporter were seeded at 1.0 x 105 cells/well in 6-well plates. 
Next day, the cells were infected with retorvirsuses containing three or four factors (day 
0). On day 3, the cells were replated onto mitomycin C-treated SNL feeder cells (48). 
The transduced cells were cultivated with ES medium containing LIF (49). Selection 
with puromycin (1.5 µg/ml) was started at day 21.  Twenty-five to 30 days after 
transduction, the number of colonies was manually counted under a phase-contrast 
microscope and recorded. Some colonies were then selected for expansion. The induction 
of human iPSC was performed as described previously (6, 50). Adult human dermal 
fibroblasts (aHDF) from the facial dermis of 36-year-old Caucasian female were 
purchased from Cell Applications, Inc. 
 
RNA isolation and reverse transcription 
The purifications of total RNA and RT-PCR were performed as previously described (1, 3, 
6, 50). The expression of L-Myc was detected with a primer set that is listed in 
Supplementary Table 5.  
 
Transformation assay in NIH3T3 cells 
NIH3T3 cells were plated at 2.5 x 104 cells/well in 24-well plates. Next day, the cells 
were infected with Myc-wild type or mutants. Two days after infection, the 
transfomation activity was determined based on the morphological changes. 
 
DNA microarray analyses 
A DNA microarray analysis was performed as previously described (50). HDF were 
retrovirally infected with wildtype or mutant Myc. Forty-eight hours after infection, 
total RNA was extracted from the cells and used for microarray experiments 
(GSE22654). Data were analyzed by the GeneSpring GX 11 software package (Agilent). 
The genes activated or suppressed by Myc proteins were selected and categorized as 
described in the Results section. According to the expression levels of these selected 
genes, hierarchical clustering of the log2 expression ratios was performed for five cancer 
cells, two normal cells (HDF and lung fibroblasts), human iPS cells (average of three 
clones; 201B2, 201B7, and 253G1), and human ES cells (average of four clones; H1, H9, 
KhES1, and KhES3). The microarray data of cancer cells and lung fibroblasts were 
obtained from GEO DataSets (adenocarcinomas; GSE13213, bladder cancer; GSE19716, 
glioblastoma; GSE10878, nasopharyngeal carcinoma; GSE15191, stromal tumor; 
GSE17018, lung fibroblasts; GSE15359). 
 
Statistical analyses 
Data are shown in averages ± standard deviations. All statistical analyses were 
performed with One-Way Repeated-Measures ANOVA and Bonferroni Post Hoc test, 
using KaleidaGraph 4 (HULINKS, Japan).  
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Figure 1 Promotion of human iPSC generation by L-Myc 
(A) The number of human iPSC colonies from HDFs transduced with or without the 
indicated Myc family genes. (n=4, **P<0.01 versus wo Myc or c-Myc).  
(B) The effect of Myc on the percentage of human iPS cell colonies per all colonies (n=4, 
**P<0.01 versus c-Myc or N-Myc).  
(C) Morphology of L-Myc hiPSC. Scale bar, 200 µm. 
 
Figure 2 Generation of mouse iPSC with L-Myc 
(A) Generation of mouse iPSC with or without the indicated Myc family genes from 
MEF containing the Nanog-GFP reporter. The raw data from five independent 
experiments are shown (Exp. No. 1-5). Each red line shows the average of five 
experiments in the indicated condition. 
(B) Effect of the Myc family genes on the percentage of GFP-positive colonies per all 
colonies (n=5, *P<0.05, **P<0.01). 
 
Figure 3 Chimeric Mice derived from L-Myc iPSC 
 (A) Frequency of germline transmission of mouse iPSC clones established without Myc 
or with either c-Myc or L-Myc. The white columns show how many iPSC clones gave rise 
to germline transmission, whereas the grey columns show how many clones were tested. 
Also shown are the percentages of germline-competent iPSC clones to all clones tested.  
(B) The cumulative overall mortality (upper panel) and morality with microscopically 
obvious tumors (lower panel) in the chimera mice derived from iPSC with c-Myc or 
L-Myc. Numbers in parentheses show the total number of animals tested in each group. 
 
Figure 4 Promotion of iPSC generation by transformation-deficient Myc 
mutants 
(A) Transformation activity of wildtype and mutants Myc in NIH3T3 cells. Scale bar, 
100 µm. 
(B) Generation of human iPSC with Myc mutants. The numbers of hiPSC colonies are 
shown (n=9, *P<0.05 versus wildtype c-Myc). 
 (C) Transformation activity of N-terminus deleted c-Myc mutants in NIH3T3 cells. 
Scale bar, 100 µm. 
(D) Generation of human iPS cells by N-terminus deleted c-Myc mutants. The numbers 
of hiPSC colonies are shown (n=3, *P<0.05 versus wildtype or dN1 c-Myc, **P<0.01 
versus wo Myc). 
 Figure 5 Genes regulated by Myc proteins 
 (A) Subgroups of the genes regulated by Myc proteins. Venn diagrams were 
constructed from the group A, B, C, and D. The numbers of the genes in each list are 
shown. These genes are listed in Supplementary Table 1. 
(B) Regulation of aHDF- or ES cell- enriched genes by Myc. The numbers of genes are 
shown whose expression is >5 fold higher or lower in hESC (H9) than in adult human 
dermal fibroblasts (aHDF) in each subgroup.  
(C) Comparison of gene expression in cancer cells, normal fibroblasts, iPSC and ESC. 
The expression levels of the genes in each subgroup in five cancer cells, two normal 
fibroblasts, human iPSC (average of three clones; 201B2, 201B7, and 253G1), and 
human ESC are shown (average of four clones; H1, H9, KhES1, and KhES3). Adeno, 
adenocarcinomas; Bladder, bladder cancer; GBM, glioblastoma; NPC, nasopharyngeal 
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Figure S1! Characterization of human L-Myc iPSC in vitro. 
(A) Immunostaining of human ES marker genes in L-Myc hiPSC. Scale bar, 500 µm. 
(B) Various tissues observed in teratomas from L-Myc hiPSC. Scale bars, 100 µm. 
(C) Human L-Myc iPS cells differentiated into several lineages of somatic cells in vitro 
through embryonic body formation. Scale bar, 100 µm. 
(D) Karyotype analysis. A normal karyotype was maintained after prolonged passages (up 
to passage 55). Fifty metaphases were analyzed for each clone. 
 
Figure S2! Characterization of mouse L-Myc iPSC in vitro. 
(A) Morphology of mouse iPSC established with L-Myc. The phase contrast (PH) and 
fluorescent images of six independent clones are shown. Scale bar, 500 µm. 
(B) RT-PCR analyses of ES marker genes and retroviral transgenes (Tg). Nanog and other 
ES marker genes expressed in iPSC with L-myc. The clones 142C2 or 142E9 were partially 
reprogrammed cells which maintain highly transgene expression of the three factors 
(Oct3/4, Sox2, and Klf4), plus either c-Myc (142C2) or L-Myc (142E9). 
(C) Hematoxylin and eosin staining of teratomas derived from mouse L-Myc iPSC. Scale 
bar, 100 µm. 
 
Figure S3 Generation of mouse iPSC without Sox2 
(A) Fluorescent (upper panel) and phase contrast (lower panel) images of mouse iPSC 
clones generated with Oct3/4, Klf4, and L-Myc. Scale bar, 500 µm. 
(B) RT-PCR analyses for the expression of ES marker genes and retroviral transgenes.  
(C) Genomic-PCR analyses for the detection of integrated transgenes. 
(D) Teratomas derived from Sox2-minus iPSC clones. Scale bar, 100 µm. 
(E) Various tissues observed in embryoid bodies from Sox2-minus iPSC clones. Scale bar, 
100 µm. 
(F) Germline transmission of a Sox2-minus iPSC clone. 
 
Figure S4 Generation of iPS cells by Myc mutants. 
(A) Generation of human iPSC with Myc mutants. The percentages of hiPSC colonies per 
all colonies are shown (n=9, *P<0.05 versus wildtype c-Myc, **P<0.01 versus wildtype 
c-Myc). 
(B) Generation of human iPS cells by N-terminus deleted c-Myc mutants. The percentages 
of hiPSC colonies per total colonies are shown (n=3, **P<0.01 versus wildtype or dN1 
c-Myc). 
Generation of mouse iPSC with Myc mutants. The numbers of GFP-positive (C) and 
percentages of GFP-positive (D) colonies are shown (n=4, **P<0.01 versus all other 
conditions except for V394D c-Myc (C), **P<0.01 versus wildtype c-Myc (D)). 
Generation of mouse iPSC with N-terminus deleted c-Myc mutants. The numbers of 
GFP-positive (E) and percentages of GFP-positive (F) colonies are shown (n=4, *P<0.05 












































































































































































































































































































































































































































































































AB062488 Homo sapiens OK/SW-cl.92 mRNA, complete cds. [AB062488]
ACTL8 Homo sapiens actin-like 8 (ACTL8), mRNA [NM_030812]
ADAM11 Homo sapiens ADAM metallopeptidase domain 11 (ADAM11), mRNA [NM_002390]
AF086124 Homo sapiens full length insert cDNA clone ZA79C08. [AF086124]
AGPAT5
Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon) (AGPAT5), mRNA
[NM_018361]
AI278811
AI278811 qo50a11.x1 NCI_CGAP_Co8 Homo sapiens cDNA clone IMAGE:1911932 3' similar to gb:K02276 MYC PROTO-ONCOGENE PROTEIN (HUMAN);,
mRNA sequence [AI278811]
AK021715 Homo sapiens cDNA FLJ11653 fis, clone HEMBA1004538. [AK021715]
AK022337 Homo sapiens cDNA FLJ12275 fis, clone MAMMA1001686. [AK022337]
ALS2CR13 Homo sapiens amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 13 (ALS2CR13), mRNA [NM_173511]
ANP32C Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member C (ANP32C), mRNA [NM_012403]
BAX Homo sapiens BCL2-associated X protein (BAX), transcript variant epsilon, mRNA [NM_138764]
BC029473 Homo sapiens cDNA clone IMAGE:4723680, **** WARNING: chimeric clone ****. [BC029473]
BC041996 Homo sapiens cDNA clone IMAGE:5310797. [BC041996]
BU567141 AGENCOURT_10393620 NIH_MGC_141 Homo sapiens cDNA clone IMAGE:6606733 5', mRNA sequence [BU567141]
C10orf95 Homo sapiens chromosome 10 open reading frame 95 (C10orf95), mRNA [NM_024886]
C20orf42 Homo sapiens chromosome 20 open reading frame 42 (C20orf42), mRNA [NM_017671]
C7orf40 Homo sapiens cDNA FLJ38860 fis, clone MESAN2011977. [AK096179]
CCDC47 Homo sapiens coiled-coil domain containing 47 (CCDC47), mRNA [NM_020198]
CCDC78 Homo sapiens coiled-coil domain containing 78 (CCDC78), transcript variant 2, mRNA [NM_173476]
CD3EAP Homo sapiens CD3e molecule, epsilon associated protein (CD3EAP), mRNA [NM_012099]
CD79B Homo sapiens CD79b molecule, immunoglobulin-associated beta (CD79B), transcript variant 1, mRNA [NM_000626]
CDC42BPG
Serine/threonine-protein kinase MRCK gamma (EC 2.7.11.1) (CDC42- binding protein kinase gamma) (Myotonic dystrophy kinase-related
CDC42-binding kinase gamma) (Myotonic dystrophy protein kinase-like alpha) (MRCK gamma) (DMPK-like gamma)....
CDK5R1 Homo sapiens cyclin-dependent kinase 5, regulatory subunit 1 (p35) (CDK5R1), mRNA [NM_003885]
CYFIP2 Homo sapiens cytoplasmic FMR1 interacting protein 2 (CYFIP2), transcript variant 2, mRNA [NM_001037332]
CYP2J2 Homo sapiens cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2), mRNA [NM_000775]
DHODH
Homo sapiens dihydroorotate dehydrogenase (DHODH), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA
[NM_001361]
DLEU1 Homo sapiens deleted in lymphocytic leukemia, 1 (DLEU1) on chromosome 13 [NR_002605]
DLL3 Homo sapiens delta-like 3 (Drosophila) (DLL3), transcript variant 2, mRNA [NM_203486]
DQ786230 Homo sapiens clone HLS_IMAGE_1706664 mRNA sequence. [DQ786230]
DRD5 Homo sapiens dopamine receptor D5 (DRD5), mRNA [NM_000798]
DUSP2 Homo sapiens dual specificity phosphatase 2 (DUSP2), mRNA [NM_004418]
ENST00000379864OTTHUMP00000018257. [Source:Uniprot/SPTREMBL;Acc:Q9H1T5] [ENST00000379864]
ERF Homo sapiens Ets2 repressor factor (ERF), mRNA [NM_006494]
EXOC6 Homo sapiens exocyst complex component 6 (EXOC6), transcript variant 2, mRNA [NM_001013848]
EXOSC5 Homo sapiens exosome component 5 (EXOSC5), mRNA [NM_020158]
FABP5 Homo sapiens fatty acid binding protein 5 (psoriasis-associated) (FABP5), mRNA [NM_001444]
FAM60A Homo sapiens family with sequence similarity 60, member A (FAM60A), mRNA [NM_021238]
FAM81A Homo sapiens family with sequence similarity 81, member A (FAM81A), mRNA [NM_152450]
FKBP4 Homo sapiens FK506 binding protein 4, 59kDa (FKBP4), mRNA [NM_002014]
FLJ38359 Homo sapiens cDNA FLJ38359 fis, clone FEBRA2000321. [AK095678]
GPSM1
Homo sapiens G-protein signalling modulator 1 (AGS3-like, C. elegans), mRNA (cDNA clone MGC:16636 IMAGE:4121647), complete cds.
[BC009979]
HSPA4L Homo sapiens heat shock 70kDa protein 4-like (HSPA4L), mRNA [NM_014278]
HSPD1
Homo sapiens heat shock 60kDa protein 1 (chaperonin) (HSPD1), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA
[NM_002156]
IGSF9 Homo sapiens immunoglobulin superfamily, member 9 (IGSF9), mRNA [NM_020789]
INPP5D Homo sapiens inositol polyphosphate-5-phosphatase, 145kDa (INPP5D), transcript variant 1, mRNA [NM_001017915]
ITPR1 Homo sapiens inositol 1,4,5-triphosphate receptor, type 1 (ITPR1), mRNA [NM_002222]
KLF15 Homo sapiens Kruppel-like factor 15 (KLF15), mRNA [NM_014079]
KLHL23 Homo sapiens kelch-like 23 (Drosophila) (KLHL23), mRNA [NM_144711]
KLK3 Homo sapiens mRNA for putative preproPSA-RP2 (KLK3 gene), transcript 2. [AJ310938]
LOC153346 Homo sapiens cDNA FLJ14284 fis, clone PLACE1005898. [AK024346]
LOC401010 Homo sapiens hypothetical LOC401010 (LOC401010) on chromosome 2 [NR_002826]
LOC442240 Homo sapiens mRNA; cDNA DKFZp781A1422 (from clone DKFZp781A1422). [CR627448]
LOC729915
PREDICTED: Homo sapiens similar to Nuclear envelope pore membrane protein POM 121 (Pore membrane protein of 121 kDa) (P145)
(LOC729915), mRNA [XR_015700]
LRRC61 Homo sapiens leucine rich repeat containing 61 (LRRC61), mRNA [NM_023942]
LRRC8B Homo sapiens leucine rich repeat containing 8 family, member B (LRRC8B), mRNA [NM_015350]
MAB21L2 Homo sapiens mab-21-like 2 (C. elegans) (MAB21L2), mRNA [NM_006439]
MGC2408 Homo sapiens hypothetical protein MGC2408 (MGC2408), mRNA [NM_032331]
MIG7 Homo sapiens MIG7 (MIG7) mRNA, complete cds. [DQ080207]
MYBBP1A Homo sapiens MYB binding protein (P160) 1a (MYBBP1A), mRNA [NM_014520]
NEFH Homo sapiens neurofilament, heavy polypeptide 200kDa (NEFH), mRNA [NM_021076]
NETO2 Homo sapiens neuropilin (NRP) and tolloid (TLL)-like 2 (NETO2), mRNA [NM_018092]
NP1247838 GB|AL162389.21|CAH73163.1 ribosomal protein L36a pseudogene 6 [Homo sapiens] [NP1247838]
NPM3 Homo sapiens nucleophosmin/nucleoplasmin, 3 (NPM3), mRNA [NM_006993]
NPW
Neuropeptide W precursor (Preproprotein L8) (hPPL8) [Contains: Neuropeptide W-23 (NPW23) (hL8); Neuropeptide W-30 (NPW30) (hL8C)].
[Source:Uniprot/SWISSPROT;Acc:Q8N729] [ENST00000329610]
NR0B1 Homo sapiens nuclear receptor subfamily 0, group B, member 1 (NR0B1), mRNA [NM_000475]
ORC2L Homo sapiens origin recognition complex, subunit 2-like (yeast) (ORC2L), mRNA [NM_006190]
P2RX5 Homo sapiens purinergic receptor P2X, ligand-gated ion channel, 5 (P2RX5), transcript variant 1, mRNA [NM_002561]
PEO1 Homo sapiens progressive external ophthalmoplegia 1 (PEO1), mRNA [NM_021830]
PRPF19 Homo sapiens PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) (PRPF19), mRNA [NM_014502]
PRR7 Homo sapiens proline rich 7 (synaptic) (PRR7), mRNA [NM_030567]
RASGEF1C Homo sapiens RasGEF domain family, member 1C (RASGEF1C), mRNA [NM_175062]
RCC1 Homo sapiens regulator of chromosome condensation 1 (RCC1), transcript variant 3, mRNA [NM_001269]
RGS16 Homo sapiens regulator of G-protein signalling 16 (RGS16), mRNA [NM_002928]
RHBDF2 Homo sapiens rhomboid 5 homolog 2 (Drosophila) (RHBDF2), transcript variant 1, mRNA [NM_024599]
RRP9 Homo sapiens RRP9, small subunit (SSU) processome component, homolog (yeast) (RRP9), mRNA [NM_004704]
SCARB1 Homo sapiens scavenger receptor class B, member 1 (SCARB1), transcript variant 1, mRNA [NM_005505]
SLC19A1 Homo sapiens solute carrier family 19 (folate transporter), member 1 (SLC19A1), mRNA [NM_194255]
SLC19A3 Homo sapiens solute carrier family 19, member 3 (SLC19A3), mRNA [NM_025243]
SLC5A6 Homo sapiens solute carrier family 5 (sodium-dependent vitamin transporter), member 6 (SLC5A6), mRNA [NM_021095]
SLC6A15 Homo sapiens solute carrier family 6, member 15 (SLC6A15), transcript variant 1, mRNA [NM_182767]
ST6GAL1 Homo sapiens ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 (ST6GAL1), transcript variant 1, mRNA [NM_173216]
TAF4B
Transcription initiation factor TFIID subunit 4B (Transcription initiation factor TFIID 105 kDa subunit) (TAFII-105) (TAFII105).
[Source:Uniprot/SWISSPROT;Acc:Q92750] [ENST00000269142]
tcag7.1239 PREDICTED: Homo sapiens similar to Huntingtin interacting protein K (LOC643438), misc RNA [XR_015268]
THC2498220 Q30VC0_DESDG (Q30VC0) Flagellar biosynthetic protein FliP, partial (8%) [THC2498220]
THC2537217
THC2654127 XKR4_MOUSE (Q5GH67) XK-related protein 4, partial (3%) [THC2654127]
THC2694828 Q3SDF2_PARTE (Q3SDF2) EPI21 protein, partial (5%) [THC2694828]
THC2730631 ARL9_HUMAN (Q6T311) ADP-ribosylation factor-like protein 9, partial (39%) [THC2730631]
TMEM97 Homo sapiens transmembrane protein 97 (TMEM97), mRNA [NM_014573]
TRIM14 Homo sapiens tripartite motif-containing 14 (TRIM14), transcript variant 1, mRNA [NM_014788]
WDR4 Homo sapiens WD repeat domain 4 (WDR4), transcript variant 2, mRNA [NM_033661]
ZNF342 Homo sapiens zinc finger protein 342 (ZNF342), mRNA [NM_145288]








ANP32A Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A), mRNA [NM_006305]
ANP32D Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member D (ANP32D), mRNA [NM_012404]
APH1A Homo sapiens anterior pharynx defective 1 homolog A (C. elegans) (APH1A), transcript variant 2, mRNA [NM_016022]
BAX Homo sapiens BCL2-associated X protein (BAX), transcript variant sigma, mRNA [NM_138765]
C10orf46 Homo sapiens chromosome 10 open reading frame 46 (C10orf46), mRNA [NM_153810]
C5orf5 Homo sapiens chromosome 5 open reading frame 5 (C5orf5), mRNA [NM_016603]
CSTF2T Homo sapiens cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa, tau variant (CSTF2T), mRNA [NM_015235]
CTSZ Homo sapiens cathepsin Z (CTSZ), mRNA [NM_001336]
EPB41 Homo sapiens erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) (EPB41), transcript variant 3, mRNA [NM_004437]
FAM60A Protein FAM60A (Tera protein homolog). [Source:Uniprot/SWISSPROT;Acc:Q9NP50] [ENST00000337682]
FLJ36874 Homo sapiens FLJ36874 protein (FLJ36874), mRNA [NM_152716]
H2AFB2 Homo sapiens H2A histone family, member B2 (H2AFB2), mRNA [NM_001017991]
HIRA Homo sapiens HIR histone cell cycle regulation defective homolog A (S. cerevisiae) (HIRA), mRNA [NM_003325]
HNRPA0 Homo sapiens heterogeneous nuclear ribonucleoprotein A0 (HNRPA0), mRNA [NM_006805]
HPDL Homo sapiens 4-hydroxyphenylpyruvate dioxygenase-like (HPDL), mRNA [NM_032756]
IPO7 Homo sapiens importin 7 (IPO7), mRNA [NM_006391]
KIFC1 Homo sapiens kinesin family member C1 (KIFC1), mRNA [NM_002263]
LIMK1 Homo sapiens LIM domain kinase 1 (LIMK1), mRNA [NM_002314]
LMNB1 Homo sapiens lamin B1 (LMNB1), mRNA [NM_005573]
LOC128192 PREDICTED: Homo sapiens similar to peptidylprolyl isomerase A isoform 1 (LOC128192), mRNA [XM_060887]
LOC284242 Homo sapiens, clone IMAGE:5745916, mRNA. [BC035844]
LOC728347 AGENCOURT_8185067 NIH_MGC_102 Homo sapiens cDNA clone IMAGE:6257517 5', mRNA sequence [BQ674642]
LOC730589 PREDICTED: Homo sapiens hypothetical protein LOC730589 (LOC730589), mRNA [XM_001126447]
MAGOH Homo sapiens mago-nashi homolog, proliferation-associated (Drosophila) (MAGOH), mRNA [NM_002370]
MEX3A Homo sapiens cDNA FLJ43493 fis, clone OCBBF3009279. [AK125482]
MORN1 Homo sapiens MORN repeat containing 1 (MORN1), mRNA [NM_024848]
MYADM Homo sapiens myeloid-associated differentiation marker (MYADM), transcript variant 2, mRNA [NM_138373]
PCDHB9 Homo sapiens protocadherin beta 9 (PCDHB9), mRNA [NM_019119]
PPP3R1 Homo sapiens protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform (PPP3R1), mRNA [NM_000945]
RNF121 Homo sapiens ring finger protein 121 (RNF121), transcript variant 1, mRNA [NM_018320]
RSRC2 Homo sapiens arginine/serine-rich coiled-coil 2 (RSRC2), transcript variant 2, mRNA [NM_198261]
SAA2 Homo sapiens serum amyloid A2 (SAA2), mRNA [NM_030754]
SLC39A7 Homo sapiens solute carrier family 39 (zinc transporter), member 7 (SLC39A7), transcript variant 1, mRNA [NM_006979]
SLC6A15 Homo sapiens solute carrier family 6, member 15 (SLC6A15), transcript variant 1, mRNA [NM_182767]
SMOC1 Homo sapiens SPARC related modular calcium binding 1 (SMOC1), transcript variant 2, mRNA [NM_022137]
TAF5L
Homo sapiens TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa (TAF5L), transcript variant 1,
mRNA [NM_014409]
THC2635386
TMED9 Homo sapiens transmembrane emp24 protein transport domain containing 9 (TMED9), mRNA [NM_017510]
UBE2E1 Homo sapiens ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) (UBE2E1), transcript variant 1, mRNA [NM_003341]
USP21 Homo sapiens ubiquitin specific peptidase 21 (USP21), transcript variant 1, mRNA [NM_012475]




BCL11A Homo sapiens B-cell CLL/lymphoma 11A (zinc finger protein) (BCL11A), transcript variant 1, mRNA [NM_022893]
EYA2 Homo sapiens eyes absent homolog 2 (Drosophila) (EYA2), transcript variant 2, mRNA [NM_172113]
LOC647968 PREDICTED: Homo sapiens similar to M-phase phosphoprotein 10 (LOC647968), mRNA [XR_018268]
MAPT Homo sapiens microtubule-associated protein tau (MAPT), transcript variant 1, mRNA [NM_016835]
MED18 Homo sapiens mediator of RNA polymerase II transcription, subunit 18 homolog (S. cerevisiae) (MED18), mRNA [NM_017638]
RFPL1S Homo sapiens ret finger protein-like 1 antisense (RFPL1S) on chromosome 22 [NR_002727]
RNF145 Homo sapiens hypothetical protein FLJ31951 (FLJ31951), mRNA [NM_144726]
THC2520867 ALU1_HUMAN (P39188) Alu subfamily J sequence contamination warning entry, partial (6%) [THC2520867]






AA081809 AA081809 zn26e08.r1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone IMAGE:548582 5', mRNA sequence [AA081809]
ABI3 Homo sapiens ABI gene family, member 3 (ABI3), mRNA [NM_016428]
AF086335 Homo sapiens full length insert cDNA clone ZD55G10. [AF086335]
AF161340 Homo sapiens HSPC077 mRNA, partial cds. [AF161340]
AF234262 Homo sapiens IL-1beta-regulated neutrophil survival protein mRNA, complete cds. [AF234262]
AK000313 Homo sapiens cDNA FLJ20306 fis, clone HEP06881. [AK000313]
AK024092 Homo sapiens cDNA FLJ14030 fis, clone HEMBA1004086. [AK024092]
AK090463 Homo sapiens mRNA for FLJ00384 protein. [AK090463]
AK124698 Homo sapiens cDNA FLJ42708 fis, clone BRAMY3007311. [AK124698]
ALOX15B Homo sapiens arachidonate 15-lipoxygenase, type B (ALOX15B), transcript variant d, mRNA [NM_001141]
ANAPC1 Homo sapiens anaphase promoting complex subunit 1 (ANAPC1), mRNA [NM_022662]
ATF3 Homo sapiens activating transcription factor 3 (ATF3), transcript variant 2, mRNA [NM_004024]
BC020341 Homo sapiens cDNA clone IMAGE:4177218. [BC020341]
BC031342 Homo sapiens, clone IMAGE:5019307, mRNA. [BC031342]
BC042947 Homo sapiens cDNA clone IMAGE:4797785. [BC042947]
CCL4 Homo sapiens chemokine (C-C motif) ligand 4 (CCL4), transcript variant 1, mRNA [NM_002984]
CD274 Homo sapiens CD274 molecule (CD274), mRNA [NM_014143]
CHD9 Homo sapiens chromodomain helicase DNA binding protein 9 (CHD9), mRNA [NM_025134]
CISH Homo sapiens cytokine inducible SH2-containing protein (CISH), mRNA [NM_145071]
DENND4A Homo sapiens DENN/MADD domain containing 4A (DENND4A), mRNA [NM_005848]
DOK3 Homo sapiens docking protein 3 (DOK3), mRNA [NM_024872]
ECH1 Homo sapiens, clone IMAGE:3858114, mRNA. [BC014786]
EDG5 Homo sapiens endothelial differentiation, sphingolipid G-protein-coupled receptor, 5 (EDG5), mRNA [NM_004230]
ENST00000291567Glucose-6-phosphate 1-dehydrogenase (EC 1.1.1.49) (G6PD). [Source:Uniprot/SWISSPROT;Acc:P11413] [ENST00000291567]
ENST00000299415Q7D724_MYCTU (Q7D724) PE_PGRS family protein (PE-PGRS FAMILY PROTEIN), partial (3%) [THC2672762]
FAIM2 Homo sapiens Fas apoptotic inhibitory molecule 2 (FAIM2), mRNA [NM_012306]
LCE1F Homo sapiens late cornified envelope 1F (LCE1F), mRNA [NM_178354]
LOC338328 Homo sapiens high density lipoprotein-binding protein (LOC338328), mRNA [NM_178172]
LOC390614 PREDICTED: Homo sapiens hypothetical LOC390614 (LOC390614), mRNA [XR_018320]
LOC642006 PREDICTED: Homo sapiens similar to Beta-glucuronidase precursor (Beta-G1) (LOC642006), mRNA [XR_018069]
MGC23985 Homo sapiens similar to AVLV472 (MGC23985), mRNA [NM_206966]
NPNT Homo sapiens nephronectin (NPNT), mRNA [NM_001033047]
NUDT22 Homo sapiens cDNA FLJ34477 fis, clone HLUNG2003833. [AK091796]
OLIG1 Homo sapiens oligodendrocyte transcription factor 1 (OLIG1), mRNA [NM_138983]
PCDH7 Homo sapiens protocadherin 7 (PCDH7), transcript variant c, mRNA [NM_032457]
PGS1 Homo sapiens phosphatidylglycerophosphate synthase 1 (PGS1), mRNA [NM_024419]
RALGDS Homo sapiens ral guanine nucleotide dissociation stimulator (RALGDS), transcript variant 1, mRNA [NM_006266]
RGPD1 Homo sapiens RANBP2-like and GRIP domain containing 1 (RGPD1), mRNA [NM_001024457]
RHOF Homo sapiens ras homolog gene family, member F (in filopodia) (RHOF), mRNA [NM_019034]
RREB1 Homo sapiens ras responsive element binding protein 1 (RREB1), transcript variant 2, mRNA [NM_002955]
SPTBN2 Homo sapiens spectrin, beta, non-erythrocytic 2 (SPTBN2), mRNA [NM_006946]
TBC1D22B Homo sapiens TBC1 domain family, member 22B (TBC1D22B), mRNA [NM_017772]
TEKT5 Homo sapiens tektin 5 (TEKT5), mRNA [NM_144674]
THC2562932 Q52M62_HUMAN (Q52M62) LOC285908 protein, partial (28%) [THC2562932]
THC2723431 Q93V73_MAIZE (Q93V73) Globulin 1 (Fragment), partial (7%) [THC2723431]
THC2752681
TRIM50 Homo sapiens tripartite motif-containing 50 (TRIM50), mRNA [NM_178125]
ZNF75 Homo sapiens zinc finger protein 75 (D8C6) (ZNF75), mRNA [NM_007131]













ACBD4 Homo sapiens acyl-Coenzyme A binding domain containing 4 (ACBD4), mRNA [NM_024722]
AK024371 Homo sapiens cDNA FLJ14309 fis, clone PLACE3000221. [AK024371]
ANKRD42 Homo sapiens ankyrin repeat domain 42 (ANKRD42), mRNA [NM_182603]
AP2B1 Homo sapiens adaptor-related protein complex 2, beta 1 subunit (AP2B1), transcript variant 2, mRNA [NM_001282]
BC034930 Homo sapiens, clone IMAGE:4579561, mRNA. [BC034930]
BC044608 Homo sapiens cDNA clone IMAGE:4827340. [BC044608]
BC070091 Homo sapiens caspase recruitment domain family, member 9, mRNA (cDNA clone MGC:87491 IMAGE:30343821), complete cds. [BC070091]
BE719776 BE719776 RC3-HT0865-260700-011-b02 HT0865 Homo sapiens cDNA, mRNA sequence [BE719776]
C19orf31 Homo sapiens chromosome 19 open reading frame 31 (C19orf31), mRNA [NM_001014373]
C7 Homo sapiens complement component 7 (C7), mRNA [NM_000587]
CEBPA Homo sapiens CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA), mRNA [NM_004364]
CHRNA4 H.sapiens mRNA for neuronal acetylcholine receptor alpha-4 subunit, exon 1. [X89741]
COX6B2 Homo sapiens cytochrome c oxidase subunit VIb polypeptide 2 (testis) (COX6B2), mRNA [NM_144613]
CR594528 full-length cDNA clone CS0DM002YC17 of Fetal liver of Homo sapiens (human) [CR594528]
CYP4F2 Homo sapiens cytochrome P450, family 4, subfamily F, polypeptide 2 (CYP4F2), mRNA [NM_001082]
DKFZP434I0714 PREDICTED: Homo sapiens hypothetical protein DKFZP434I0714 (DKFZP434I0714), mRNA [XM_929673]
DOCK3 Homo sapiens dedicator of cytokinesis 3 (DOCK3), mRNA [NM_004947]
ECSM2 Homo sapiens endothelial cell-specific molecule 2 (ECSM2), mRNA [NM_001077693]
EDA2R Homo sapiens ectodysplasin A2 receptor (EDA2R), mRNA [NM_021783]
ENST00000302096bA299N6.3 (LOC198437), mRNA [Source:RefSeq_dna;Acc:NM_001007125] [ENST00000302096]
ENST00000320010Putative uncharacterized protein C11orf37. [Source:Uniprot/SWISSPROT;Acc:Q96N53] [ENST00000320010]
ENST00000378644Homo sapiens, clone IMAGE:5728979, mRNA. [BC035731]
EPPK1 Homo sapiens epiplakin 1 (EPPK1), mRNA [NM_031308]
FLJ35934 Homo sapiens cDNA FLJ35934 fis, clone TESTI2011315. [AK093253]
FMO5 Homo sapiens flavin containing monooxygenase 5 (FMO5), mRNA [NM_001461]
FRMD4A Homo sapiens FERM domain containing 4A (FRMD4A), mRNA [NM_018027]
GEFT Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA [NM_133483]
HSD17B1 Homo sapiens, clone IMAGE:5443970, mRNA, partial cds. [BC033110]
IQSEC1 Homo sapiens IQ motif and Sec7 domain 1 (IQSEC1), mRNA [NM_014869]
KISS1R Homo sapiens KISS1 receptor (KISS1R), mRNA [NM_032551]
KRT18P40
PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 18 (Cytokeratin-18) (CK-18) (Keratin-18) (K18) (LOC390904), mRNA
[XR_017288]
LOC145694 Homo sapiens cDNA FLJ32231 fis, clone PLACE6004491. [AK056793]
LOC339344 Homo sapiens hypothetical protein LOC339344 (LOC339344), mRNA [NM_001012643]
LOC392617 PREDICTED: Homo sapiens similar to slit homolog 1 (LOC392617), mRNA [XM_001132524]
LOC643594 PREDICTED: Homo sapiens similar to CG13731-PA (LOC643594), mRNA [XM_926898]
LOC646643
Putative uncharacterized serine/threonine-protein kinase SgK069 (EC 2.7.11.1) (Sugen kinase 69).
[Source:Uniprot/SWISSPROT;Acc:P0C263] [ENST00000344158]
LOC646960 PREDICTED: Homo sapiens similar to transmembrane protease, serine 9 (LOC646960), mRNA [XM_929928]
LOC650392 Homo sapiens hypothetical protein LOC650392, mRNA (cDNA clone IMAGE:5242623), partial cds. [BC028099]
LOC730498 PREDICTED: Homo sapiens similar to Zinc finger protein 561 (LOC730498), mRNA [XR_015158]
LOC731997 PREDICTED: Homo sapiens hypothetical protein LOC731997 (LOC731997), mRNA [XM_001131542]
LRP3 Homo sapiens low density lipoprotein receptor-related protein 3 (LRP3), mRNA [NM_002333]
MGC21874 Homo sapiens cDNA FLJ45019 fis, clone BRAWH3015825. [AK126966]
MGC34800 Homo sapiens hypothetical protein MGC34800, mRNA (cDNA clone MGC:34800 IMAGE:5167909), complete cds. [BC029861]
MOP-1 Homo sapiens mRNA for MOP-1, complete cds. [AB014771]
MYCN Homo sapiens v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (MYCN), mRNA [NM_005378]
NEUROG1 Homo sapiens neurogenin 1 (NEUROG1), mRNA [NM_006161]
NEUROG3 Homo sapiens neurogenin 3 (NEUROG3), mRNA [NM_020999]
NKD2 Homo sapiens naked cuticle homolog 2 (Drosophila) (NKD2), mRNA [NM_033120]
NP511100 GB|AB065467.1|BAC05726.1 seven transmembrane helix receptor [Homo sapiens] [NP511100]
PAX7 Homo sapiens paired box gene 7 (PAX7), transcript variant 2, mRNA [NM_013945]
PCSK1N Homo sapiens proprotein convertase subtilisin/kexin type 1 inhibitor (PCSK1N), mRNA [NM_013271]
PIP5K1C Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma (PIP5K1C), mRNA [NM_012398]
PRLH Homo sapiens prolactin releasing hormone (PRLH), mRNA [NM_015893]
PSORS1C2 Homo sapiens psoriasis susceptibility 1 candidate 2 (PSORS1C2), mRNA [NM_014069]
RHBDL1 Homo sapiens rhomboid, veinlet-like 1 (Drosophila) (RHBDL1), mRNA [NM_003961]
S72478
BCR...ABL {b3/a3 junction, translocation breakpoint} [human, Japanese CML patient 1 and ALL patient 2, peripheral blood, mononuclear
cells, mRNA Mutant, 3 genes, 140 nt]. [S72478]
SAMD10 Homo sapiens sterile alpha motif domain containing 10 (SAMD10), mRNA [NM_080621]
SOX8 Homo sapiens SRY (sex determining region Y)-box 8 (SOX8), mRNA [NM_014587]
SP5 Homo sapiens Sp5 transcription factor (SP5), mRNA [NM_001003845]
SPSB4 Homo sapiens splA/ryanodine receptor domain and SOCS box containing 4 (SPSB4), mRNA [NM_080862]
THC2545702
THC2585656 Q6NVT1_XENTR (Q6NVT1) RNA binding motif protein 25, partial (7%) [THC2585656]
THC2636500
THC2669063 AI500335 tm95e03.x1 NCI_CGAP_Brn25 Homo sapiens cDNA clone IMAGE:2165884 3', mRNA sequence [AI500335]
THC2678411 Q34Z38_9GAMM (Q34Z38) Outer membrane efflux protein precursor, partial (5%) [THC2678411]
THC2689192 Q7XC69_ORYSA (Q7XC69) Expressed protein, partial (6%) [THC2689192]
THC2719256 BE147120 PM2-HT0224-221099-001-b10 HT0224 Homo sapiens cDNA, mRNA sequence [BE147120]
TNXB Homo sapiens tenascin XB (TNXB), transcript variant XB, mRNA [NM_019105]
TRIM35 Homo sapiens tripartite motif-containing 35 (TRIM35), transcript variant 2, mRNA [NM_171982]
TSPAN10 Homo sapiens tetraspanin 10 (TSPAN10), mRNA [NM_031945]
U01925 Human BTK region clone 2f10-rpi mRNA. [U01925]
VASH2 Homo sapiens vasohibin 2 (VASH2), mRNA [NM_024749]
Y10152 H.sapiens mRNA for CRF2 receptor, beta isoform, aberrantly spliced, (94bp deletion). [Y10152]
ZNF687 Homo sapiens zinc finger protein 687 (ZNF687), mRNA [NM_020832]
















ALDOA Homo sapiens aldolase A, fructose-bisphosphate (ALDOA), transcript variant 2, mRNA [NM_184041]
ANKDD1A Homo sapiens cDNA FLJ25870 fis, clone CBR02141. [AK098736]
AW167080 AW167080 xg70g01.x1 NCI_CGAP_Ut4 Homo sapiens cDNA clone IMAGE:2633712 3', mRNA sequence [AW167080]
BC028232 Homo sapiens, clone IMAGE:5221276, mRNA, partial cds. [BC028232]
BC036435 Homo sapiens cDNA clone IMAGE:4816083, partial cds. [BC036435]
BHLHB4 Homo sapiens basic helix-loop-helix domain containing, class B, 4 (BHLHB4), mRNA [NM_080606]
BM547196 BM547196 AGENCOURT_6499364 NIH_MGC_124 Homo sapiens cDNA clone IMAGE:5730270 5', mRNA sequence [BM547196]
C16orf3 Homo sapiens chromosome 16 open reading frame 3 (C16orf3), mRNA [NM_001214]
C21orf58 Homo sapiens chromosome 21 open reading frame 58 (C21orf58), transcript variant 2, mRNA [NM_199071]
CACNA1E Homo sapiens calcium channel, voltage-dependent, R type, alpha 1E subunit (CACNA1E), mRNA [NM_000721]
CCDC108 Homo sapiens coiled-coil domain containing 108 (CCDC108), transcript variant 1, mRNA [NM_194302]
CLEC4M Homo sapiens C-type lectin domain family 4, member M (CLEC4M), transcript variant 4, mRNA [NM_214677]
CMIP Homo sapiens c-Maf-inducing protein (CMIP), transcript variant C-mip, mRNA [NM_198390]
CPXM1 Homo sapiens carboxypeptidase X (M14 family), member 1 (CPXM1), mRNA [NM_019609]
CYB561D1 Homo sapiens cytochrome b-561 domain containing 1 (CYB561D1), mRNA [NM_182580]
DDX6 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX6), mRNA [NM_004397]
DYRK1A Homo sapiens mRNA for MNB/DYRK protein kinase, partial cds, alternatively spliced transcript MNB31. [AB015282]
ENST00000324745Homo sapiens mRNA for FLJ00388 protein. [AK090467]
ENST00000359589
FLJ35390 Homo sapiens hypothetical protein FLJ35390, mRNA (cDNA clone IMAGE:4328569), with apparent retained intron. [BC024303]
FOXRED2 Homo sapiens FAD-dependent oxidoreductase domain containing 2 (FOXRED2), mRNA [NM_024955]
GH2 Homo sapiens growth hormone 2 (GH2), transcript variant 3, mRNA [NM_022558]
IFITM5 Homo sapiens interferon induced transmembrane protein 5 (IFITM5), mRNA [NM_001025295]
KIAA1545 Homo sapiens XTP9 (XTP9) mRNA, complete cds. [AF490258]
KLK3 Homo sapiens prostate-specific antigen variant 2 mRNA, complete cds, alternatively spliced. [AF335478]
LCE1D Homo sapiens late cornified envelope 1D (LCE1D), mRNA [NM_178352]
LOC146325 Homo sapiens similar to hypothetical protein FLJ13841 (LOC146325), mRNA [NM_145270]
LOC649294 Homo sapiens cDNA FLJ33940 fis, clone CTONG2018069. [AK091259]
LOC728449 annexin A8 [Source:RefSeq_peptide;Acc:NP_001621] [ENST00000335083]
LOC728864 PREDICTED: Homo sapiens similar to Mucin-2 precursor (Intestinal mucin 2) (LOC728864), mRNA [XM_001128654]
LOC729956 PREDICTED: Homo sapiens hypothetical protein LOC729956 (LOC729956), mRNA [XM_001131873]
LOC90113 PREDICTED: Homo sapiens hypothetical protein BC009862 (LOC90113), mRNA [XM_291077]
LYPD3 Homo sapiens LY6/PLAUR domain containing 3 (LYPD3), mRNA [NM_014400]
MCOLN2 Homo sapiens mucolipin 2 (MCOLN2), mRNA [NM_153259]
MGC13057 Homo sapiens hypothetical protein MGC13057 (MGC13057), transcript variant 4, mRNA [NM_032321]
MLXIPL Homo sapiens MLX interacting protein-like (MLXIPL), transcript variant 4, mRNA [NM_032954]
NKX1-2 PREDICTED: Homo sapiens NK1 transcription factor related, locus 2 (Drosophila) (NKX1-2), mRNA [XM_372331]
NP111687 GB|L33988.1|AAA74365.1 ORF [NP111687]
NRSN2 Homo sapiens neurensin 2 (NRSN2), mRNA [NM_024958]
PCSK1N Homo sapiens proprotein convertase subtilisin/kexin type 1 inhibitor (PCSK1N), mRNA [NM_013271]
POU3F3 Homo sapiens POU domain, class 3, transcription factor 3 (POU3F3), mRNA [NM_006236]
PRIC285 Homo sapiens peroxisomal proliferator-activated receptor A interacting complex 285 (PRIC285), transcript variant 2, mRNA [NM_033405]
RFX3 Transcription factor RFX3. [Source:Uniprot/SWISSPROT;Acc:P48380] [ENST00000382004]
SF3A2 Homo sapiens splicing factor 3a, subunit 2, 66kDa (SF3A2), mRNA [NM_007165]
SPPL2B Homo sapiens signal peptide peptidase-like 2B (SPPL2B), transcript variant 3, mRNA [NM_001077238]
SYNGR4 Homo sapiens synaptogyrin 4 (SYNGR4), mRNA [NM_012451]
TANC2 Homo sapiens mRNA for putative ankyrin-repeat containing protein (ORF1). [AJ278120]
THC2503530 AA360388 EST69518 T-cell lymphoma Homo sapiens cDNA 5' end similar to EST containing Alu repeat, mRNA sequence [AA360388]
THC2529614 Q3VHI9_9SPHN (Q3VHI9) Manganese and iron superoxide dismutase precursor, partial (8%) [THC2529614]
THC2532927 Q7Z637_HUMAN (Q7Z637) PTPN18 protein, partial (13%) [THC2532927]
THC2658813
THC2678806 HESX1_HUMAN (Q9UBX0) Homeobox expressed in ES cells 1 (Homeobox protein ANF) (hAnf), partial (70%) [THC2678806]
THC2689579 BPAP_BOVIN (P84291) Pregnancy-associated protein bPAP (Fragments), partial (10%) [THC2689579]
THC2717131 Q7NI46_GLOVI (Q7NI46) Cytochrome c550, partial (8%) [THC2717131]
THC2752750
TLE6 Homo sapiens transducin-like enhancer of split 6 (E(sp1) homolog, Drosophila) (TLE6), mRNA [NM_024760]
UCN2 Homo sapiens urocortin 2 (UCN2), mRNA [NM_033199]
Supplementary Table 2! Primers used for cloning 
Genes Sequences 
CAC CAT GGA CTA CGA CTC GTA CCA GCA CT 
Hu-L-Myc 
TTA GTA GCC AGT GAG GTA TGC AAT TC 
CAC CAT GCC GAG CTG CTC CAC GTC CAC C 
Hu-N-Myc 
GAA AAT TGA ACA CGC TCG GAC TTG CTA G 
 
Supplementary Table 3! Primers used for deletion mutants 
Genes Sequences 
CAC CAT GCT CGA CTA CGA CTC GGT GCA GCC 
Hu-c-Myc-dN1 (dN1) 
TTA CGC ACA AGA GTT CCG TAG CTG TTC AAG 
CAC CAT GCC CCC GGC GCC CAG CGA GGA TAT 
Hu-c-Myc-dN2 (dN2) 
TTA CGC ACA AGA GTT CCG TAG CTG TTC AAG 
 
Supplementary Table 4! Primers used for site-directed mutagenesis 
Genes Sequences 
CAG GAC TGT ATG GAG AGC GGT TTC TC 
Ms-c-Myc-W136E 
GAG AAA CCG CTC TCC ATA CAG TCC TG 
GCC CCC AAG GTA GAT ATC CTC AAA AAA G 
Ms-c-Myc-V394D 
CTT TTT TGA GGA TAT CTA CCT TGG GGG C 
GAA AAG GAC TTA CCG AGG AAA CGA CG 
Ms-c-Myc-L420P 
CGT CGT TTC CTC GGT AAG TCC TTT TC 
AGA AAA GGC AGC CCC GGT GTC GGC A 
Ms-L-Myc-L351P 
TGC CGA CAC CGG GGC TGC CTT TTC T 
 
Supplementary Table 5! Primers used for RT-PCR 
Genes Sequences 
CAC TGA GGA CGT GAC CAA GA 
Ms-L-Myc Total 
TTA GTA GCC ACT GAG GTA CGC GAT TCT CTT 
CAC TGA GGA CGT GAC CAA GA 
Ms-L-Myc Tg 
GAC ATG GCC TGC CCG GTT ATT ATT 
GTG AGT CCC CCA CCT GTA GA 
Hu-L-Myc Total 
TTA GTA GCC AGT GAG GTA TGC AAT TC 
GTG AGT CCC CCA CCT GTA GA 
Hu-L-Myc Tg 
GAC ATG GCC TGC CCG GTT ATT ATT 
 
